COMMUNIQUÉS West-GlobeNewswire

Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network
14/09/2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced that its wholly owned clinical research Site Management Organization (SMO) [...]
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
14/09/2026
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated A Type C [...]
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
14/09/2026
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage [...]
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
14/09/2026
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules LOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biodesix, [...]
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
14/09/2026
KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first [...]
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
14/09/2026
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to [...]
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
14/09/2026
Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic [...]
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
14/09/2026
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in [...]
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
14/09/2026
Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for [...]
PetMeds Appoints Andrew Parry as Chief Technology Officer
14/09/2026
DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, [...]
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
14/09/2026
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS [...]
Wellthy Acquires Cleo as Two Leaders Come Together to Create the Singular Platform for Family Care
14/09/2026
Wellthy's acquisition of Cleo brings together two leaders in family care, expanding support for employers, health plans, and families. NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Wellthy today announced its acquisition [...]
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
14/09/2026
Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
Paralyzed Marine Veteran Stands and Walks at Enjoy Illinois 300 as Patriot Mobile Puts SoldierStrong on Ty Dillon's No. 10
14/09/2026
STAMFORD, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- SoldierStrong, the national nonprofit committed to delivering revolutionary medical technologies to America's veterans, brought its mission to the NASCAR Cup Series [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2026
14/09/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 7 septembre au 11 septembre 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026
14/09/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 7th September to 11th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial [...]
GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF
14/09/2026
L’acquisition par GENFIT du nangibotide, un candidat-médicament au profil différencié en phase avancée de développement clinique, renforce le portefeuille de thérapies innovantes de la Société adressant d’importants [...]
GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
14/09/2026
GENFIT's acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needs The investigation in Phase 2 is supported by a [...]
KFSH Riyadh Records Zero High-Risk Findings Across Nearly 1,800 Measures in JCI Reaccreditation
14/09/2026
RIYADH, Saudi Arabia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has secured reaccreditation as an Academic Medical Center from Joint Commission International [...]

Pages